Our team of executives, pharmaceutical developers, and scientists envision a world where every patient has options and access to the care they need at every stage of disease. We are focused on transitioning strong pre-clinical scientific evidence into actionable treatments to expand options for patients with rare and aggressive cancers. We are a versatile team that puts the patient first.